SecBot SecBot
6-K ·Filed Jul 8, 2026

CMMB

Chemomab Therapeutics Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed4mo ago SEC0001178913-26-003442
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a transformative reverse-merger for CMMB, which will deliver a ~$150M combined entity with $30M+ in new cash and a clear pipeline catalyst in RA. The merger provides a path to a Nasdaq listing as SCIP with institutional sponsorship. Monitor the shareholder vote, SEC S-4 filing, and Israeli tax ruling as near-term catalysts. The transition from CMMB to SCIP creates an event-driven opportunity for long-biased traders willing to hold through the Q4 2026 close window.

DirectionBullish
Confidencehigh
Horizonmonths

nebokitug

◆ Mixed Named in this 6-K
Impact
Phase
Phase 2 (complete); preparing Phase 3
Time to market
At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
Next catalyst
None dated

What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.97
T+0 close · Jul 8, 2026 · via day close
Latest settled
−39.59%
T+60 · $1.19
Vs SPY
−41.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $1.97entry
  2. T+1 · 4mo ago −7.11%α −7.95% · $1.83
  3. T+5 · 4mo ago −22.34%α −23.20% · $1.53
  4. T+20 · 3mo ago −11.17%α −14.44% · $1.75
  5. T+60 · 7w ago −39.59%α −41.91% · $1.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation, a precision medicine company. The combined company, valued at $150 million, will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Chemomab shareholders will own approximately 32% of the combined company before a concurrent $30 million PIPE. The merger is expected to close in Q4 2026.

Key Facts

  • Combined company pre-money valuation of $150 million ($48 million for Chemomab, $102 million for Scipher, subject to adjustment for Scipher's indebtedness)
  • Chemomab equity holders expected to own approximately 32% of combined company; Scipher equity holders approximately 68%, pre-PIPE
  • Concurrent PIPE investment of not less than $30 million from a syndicate led by Northpond Ventures including Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger
  • Post-merger company to focus on advancing nebokitug into a Phase 2 RA trial with AI-powered precision medicine enrollment using Scipher's PrismRA test
  • Phase 2 RA readout expected H1 2028; cash runway expected into H2 2028
  • Chemomab pre-merger shareholders to receive CVRs for cash payments upon achievement of nebokitug milestones
  • Merger expected to close in Q4 2026; combined company to trade under ticker SCIP on Nasdaq

Financial Impact

Combined company valued at $150 million pre-PIPE; Chemomab valued at $48 million, Scipher at $102 million (subject to adjustment for Scipher's indebtedness). Concurrent PIPE of at least $30 million at a valuation of $150 million with 100% warrant coverage at 50% of the PIPE valuation.

shareholder valuecash runwaymarket capitalization

Risk Factors

  • Transaction may not close due to failure of shareholder approval, regulatory hurdles, or failure to obtain Israeli tax rulings: $2M termination fee payable by Chemomab to Scipher in certain events
  • Chemomab must have Net Cash of at least $0 at closing; no Indebtedness
  • Phase 2 RA data readout not expected until H1 2028, several years away
  • Lock-up agreements restrict selling by key Chemomab and Scipher insiders after closing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-003442
Exhibit: exhibit_99-1.htm0001178913-26-003442
Document: zk2635653.htm0001178913-26-003442
Document: 0001178913-26-003442-index-headers.html0001178913-26-003442
Document: 0001178913-26-003442-index.html0001178913-26-003442
Document: 0001178913-26-003442.txt0001178913-26-003442

Track record

15 reports on CMMB

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  2. Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  3. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  5. Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  6. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
  7. Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
  8. Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
  9. Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
  10. Jul 8, 202618w ago 6-K Bullish 7/10 Viewing Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026